At the news
? BULLISHIMPACT 6/10 PRESS-RELEASE filed Mar 30, 2026 at 07:00 ET
NRx Pharmaceuticals' subsidiary Hope Therapeutics partnered with Emobot Health to deploy an AI-powered 'Depression Thermometer' across its interventional psychiatry clinics. The technology enables passive, real-time monitoring of depression and anxiety via smartphone, aiming to reduce relapse rates and improve patient outcomes through early intervention.
- Hope Therapeutics (NRXP subsidiary) partnered with Emobot Health to integrate AI-driven emotional monitoring in its clinic network.
- Emobot's 'Depression Thermometer' passively analyzes facial expressions, vocal tones, and actigraphy to detect early relapse in TRD patients.
- Clinical validation shows strong correlation with MADRS (r=0.89) and PHQ-9 (r=0.83) scales.
- The platform aims to double patient success rates by enabling timely recapture interventions like maintenance ketamine or TMS.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access